Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R.

Eur Respir J. 2018 Aug 23. pii: 1801020. doi: 10.1183/13993003.01020-2018. [Epub ahead of print] No abstract available.

PMID:
30139779
2.

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.

PMID:
29668352
3.

Both moderate and severe exacerbations accelerate physical activity decline in COPD patients.

Demeyer H, Costilla-Frias M, Louvaris Z, Gimeno-Santos E, Tabberer M, Rabinovich RA, de Jong C, Polkey MI, Hopkinson NS, Karlsson N, Serra I, Vogiatzis I, Troosters T, Garcia-Aymerich J; PROactive Consortium.

Eur Respir J. 2018 Jan 25;51(1). pii: 1702110. doi: 10.1183/13993003.02110-2017. Print 2018 Jan. No abstract available.

PMID:
29371385
4.

Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.

5.

Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 May 1;197(9):1230-1231. doi: 10.1164/rccm.201711-2313LE. No abstract available.

PMID:
29241016
6.

Reply to Suissa and Ariel: The FULFIL Trial.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2018 Feb 15;197(4):542-543. doi: 10.1164/rccm.201709-1831LE. No abstract available.

PMID:
28950068
7.

Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.

Ismaila AS, Birk R, Shah D, Zhang S, Brealey N, Risebrough NA, Tabberer M, Zhu CQ, Lipson DA.

Adv Ther. 2017 Sep;34(9):2163-2172. doi: 10.1007/s12325-017-0604-x. Epub 2017 Sep 5.

8.

Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials.

Jones PW, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Apr 1;4(2):150-158. doi: 10.15326/jcopdf.4.2.2017.0132.

9.

St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database.

Müllerova H, Gelhorn H, Wilson H, Benson VS, Karlsson N, Menjoge S, Rennard SI, Tabberer M, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 28;4(2):141-149. doi: 10.15326/jcopdf.4.2.2017.0131.

10.

Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients.

Jones PW, Gelhorn H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 21;4(2):132-140. doi: 10.15326/jcopdf.4.2.2017.0129.

11.

Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire.

Jones PW, Gelhorn H, Wilson H, Karlsson N, Menjoge S, Müllerova H, Rennard SI, Tal-Singer R, Merrill D, Tabberer M.

Chronic Obstr Pulm Dis. 2017 Mar 2;4(2):124-131. doi: 10.15326/jcopdf.4.2.2017.0130.

12.

The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset.

Tabberer M, Benson VS, Gelhorn H, Wilson H, Karlsson N, Müllerova H, Menjoge S, Rennard SI, Tal-Singer R, Merrill D, Jones PW.

Chronic Obstr Pulm Dis. 2017 Mar 13;4(2):112-123. doi: 10.15326/jcopdf.4.2.2017.0128.

13.

The COPD Biomarkers Qualification Consortium St George's Respiratory Questionnaire Manuscripts: Output of a Consortium to Advance Drug Development.

Tabberer M, Jones PW.

Chronic Obstr Pulm Dis. 2017 Feb 28;4(2):109-111. doi: 10.15326/jcopdf.4.2.2017.0127. No abstract available.

14.

Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease".

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1083-1084. doi: 10.1164/rccm.201704-0818LE. No abstract available.

PMID:
28534669
15.

FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, Pascoe SJ.

Am J Respir Crit Care Med. 2017 Aug 15;196(4):438-446. doi: 10.1164/rccm.201703-0449OC.

PMID:
28375647
16.

Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler versus a multi-dose inhaler in patients with chronic obstructive pulmonary disease.

Chan R, Sousa AR, Hynds P, Homayoun-Valiani F, Edwards D, Tabberer M.

Pulm Pharmacol Ther. 2017 Apr;43:12-19. doi: 10.1016/j.pupt.2017.01.009. Epub 2017 Jan 21.

PMID:
28115223
17.

Interpreting patient-reported outcomes from clinical trials in COPD: a discussion.

Jones PW, Rennard S, Tabberer M, Riley JH, Vahdati-Bolouri M, Barnes NC.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 7;11:3069-3078. eCollection 2016. Review.

18.

Assessment of the efficacy and safety of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler in patients with asthma.

Chan R, Sousa AR, Mallett S, Hynds P, Homayoun-Valiani F, Tabberer M, Mehta R.

Pulm Pharmacol Ther. 2016 Dec;41:19-24. doi: 10.1016/j.pupt.2016.09.002. Epub 2016 Sep 4.

PMID:
27599598
19.

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.

Riley JH, Tabberer M, Richard N, Donald A, Church A, Harris SS.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 16;11:1873-80. doi: 10.2147/COPD.S109121. eCollection 2016.

20.

Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease.

Tabberer M, Gonzalez-McQuire S, Muellerova H, Briggs AH, Rutten-van Mölken MPMH, Chambers M, Lomas DA.

Med Decis Making. 2017 May;37(4):440-452. doi: 10.1177/0272989X16662009. Epub 2016 Aug 2.

PMID:
27486218
21.

Mapping the COPD Assessment Test onto EQ-5D.

Hoyle CK, Tabberer M, Brooks J.

Value Health. 2016 Jun;19(4):469-77. doi: 10.1016/j.jval.2016.01.005. Epub 2016 Apr 1.

22.

Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model.

Briggs AH, Baker T, Risebrough NA, Chambers M, Gonzalez-McQuire S, Ismaila AS, Exuzides A, Colby C, Tabberer M, Muellerova H, Locantore N, Rutten van Mölken MPMH, Lomas DA.

Med Decis Making. 2017 May;37(4):469-480. doi: 10.1177/0272989X16653118. Epub 2016 Jun 17.

PMID:
27317436
23.

Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey.

Müllerová H, Landis SH, Aisanov Z, Davis KJ, Ichinose M, Mannino DM, Maskell J, Menezes AM, van der Molen T, Oh YM, Tabberer M, Han MK.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 27;11:881-90. doi: 10.2147/COPD.S102280. eCollection 2016. Erratum in: Int J Chron Obstruct Pulmon Dis. 2017 Mar 15;12 :859.

25.

Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study.

Exuzides A, Colby C, Briggs AH, Lomas DA, Rutten-van Mölken MPMH, Tabberer M, Chambers M, Muellerova H, Locantore N, Risebrough NA, Ismaila AS, Gonzalez-McQuire S.

Med Decis Making. 2017 May;37(4):453-468. doi: 10.1177/0272989X15610781. Epub 2015 Oct 8.

PMID:
26449490
26.

The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease.

Gimeno-Santos E, Raste Y, Demeyer H, Louvaris Z, de Jong C, Rabinovich RA, Hopkinson NS, Polkey MI, Vogiatzis I, Tabberer M, Dobbels F, Ivanoff N, de Boer WI, van der Molen T, Kulich K, Serra I, Basagaña X, Troosters T, Puhan MA, Karlsson N, Garcia-Aymerich J; PROactive consortium.

Eur Respir J. 2015 Oct;46(4):988-1000. doi: 10.1183/09031936.00183014. Epub 2015 May 28.

27.

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.

Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.

Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14.

PMID:
24835833
28.

Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care.

Müllerová H, Lu C, Li H, Tabberer M.

PLoS One. 2014 Jan 10;9(1):e85540. doi: 10.1371/journal.pone.0085540. eCollection 2014.

29.

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.

Chest. 2014 May;145(5):981-991. doi: 10.1378/chest.13-1579.

PMID:
24385182
30.

Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease.

Wilcox TK, Chen WH, Howard KA, Wiklund I, Brooks J, Watkins ML, Cates CE, Tabberer MM, Crim C.

Health Qual Life Outcomes. 2013 Nov 14;11:196. doi: 10.1186/1477-7525-11-196.

31.

Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease.

Watkins ML, Wilcox TK, Tabberer M, Brooks JM, Donohue JF, Anzueto A, Chen WH, Crim C.

BMJ Open. 2013 Oct 22;3(10):e003048. doi: 10.1136/bmjopen-2013-003048.

32.

How do children and their caregivers perceive the benefits of inhaled asthma therapy?

Gilchrist FJ, Brady M, Gallop K, Wild DJ, Tabberer M, Jacques L, Lenney W.

J Asthma. 2012 Jun;49(5):552-6. doi: 10.3109/02770903.2012.672610. Epub 2012 Apr 10.

PMID:
22486488
33.

Tests of the responsiveness of the COPD assessment test following acute exacerbation and pulmonary rehabilitation.

Jones PW, Harding G, Wiklund I, Berry P, Tabberer M, Yu R, Leidy NK.

Chest. 2012 Jul;142(1):134-140. doi: 10.1378/chest.11-0309.

PMID:
22281796
34.

Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores.

Jones PW, Tabberer M, Chen WH.

BMC Pulm Med. 2011 Aug 11;11:42. doi: 10.1186/1471-2466-11-42.

35.

Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden.

Lees M, Roberts G, Tabberer M, DasGupta R, Finnern HW; RLS Health Economic Study Group.

Curr Med Res Opin. 2008 Oct;24(10):2919-30. doi: 10.1185/03007990802344594 . Epub 2008 Sep 15.

PMID:
18796188
36.

Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.

Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J.

Curr Med Res Opin. 2008 May;24(5):1237-54. doi: 10.1185/030079908X291985 . Epub 2008 Mar 19. Review.

PMID:
18355421
37.

Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.

Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, Gosden T, Rudge H.

Curr Med Res Opin. 2007 May;23(5):1147-59.

PMID:
17519082
38.

Economic burden of post-acute myocardial infarction heart failure in the United Kingdom.

Lacey L, Tabberer M.

Eur J Heart Fail. 2005 Jun;7(4):677-83. Review.

39.

Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.

Dixon S, McKeen E, Tabberer M, Paisley S.

Pharmacoeconomics. 2004;22(7):421-33. Review.

PMID:
15137881

Supplemental Content

Loading ...
Support Center